Pramipexole right useful in patients with early breast cancer
Recently, the American Society of Clinical Oncology (ASCO) 2006 will be announced in the middle of the ATAC (Pramipexole, tamoxifen alone or in combination) trial of bone health Asian Group 5 updated analysis : If postmenopausal patients with early breast cancer treatment at the beginning of normal bone density, then they by aromatase inhibitor anastrozole treatment five years after its osteoporosis rate will not increase. The first results of the study showed anastrozole on bone health. In addition, the meeting's other research data confirmed that the same disease treatment, Pramipexole treatment benefit than tamoxifen.
More...Breast Cancer: breast cancer Treatment, bone, tamoxifen, treatment